Following the G20, Joerg Reinhardt, Chairman of the Novartis Board of Directors, reflects on how to fight rising antimicrobial resistance
ZURICH, Switzerland, July 20, 2017/3BL Media/ – Two weeks ago, G20 leaders committed to working together to address one of the world’s most pressing and perplexing security threats: antimicrobial resistance (AMR) – a fierce and evolving adversary against which conventional therapeutic weapons are of no use.
In two articles in the Lancet Infectious Diseases, the Novartis Foundation and its partners review the historic and future innovations and game-changing strategies in leprosy elimination, calling for a global effort to make leprosy history.
July 10, 2017 /3BL Media/ - On July 7th, 2017 the Novartis Foundation and its partners published two articles that call for a global effort to make leprosy history. The reviews have been published in the Lancet Infectious Diseases, a leading journal in infectious diseases.[i]
Novartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch the Novartis Access program.
July 6, 2017 /3BL Media/ -- We are pleased to announce that Novartis and the Ministry of Health of Uganda have signed a Memorandum of Understanding to implement Novartis Access in Uganda. Novartis Access medicines will be made available to patients in public health facilities through the National Medical Stores and through faith-based health services. The program will also cover capacity-building activities, including NCD prevention, diagnosis and treatment.
Today in Rio de Janeiro, Brazil, researchers, policy makers and public partners with a shared interest in determining strategies to detect leprosy and stop its global transmission come together
May 30, 2017 /3BL Media/ - On May 30, 2017 together with the Oswaldo Cruz Foundation (Fiocruz), a premier research institution in Brazil focused on public health, the Novartis Foundation is co-hosting an expert meeting entitled ‘Strategies to detect and interrupt the global transmission of leprosy’ in Rio de Janeiro, Brazil.
Pharmaceutical companies have long experience in measuring the impact of their business programs. The same should apply to their access-to-medicine efforts
Richard Laing, from the Boston University (BU) School of Public Health and former World Health Organization official, says that many efforts to expand access to medicines fail to gather sufficient evidence on how effective they are. His team at BU recently issued a study highlighting these gaps, and emphasizing the need for companies to better document the impact of their programs.
Making our cities into places of wellbeing, exciting growth and opportunity will require every sector to join forces on urban health, says Dr. Ann Aerts, Head of the Novartis Foundation.
By Dr. Ann Aerts, Head of the Novartis Foundation
Walking through the wealthier streets of cities like Geneva, London or New York, it seems that health and fitness is an international obsession. National food chains boast of fresh ingredients, light options, and low-fat meals. Shelves are stacked with the trendiest superfoods – quinoa, chia seeds, kale and avocado.
Better Hearts Better Cities is an initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension
Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension.
Non-communicable diseases (NCDs), including cardiovascular disease, are a growing health crisis with 75% of NCD deaths occurring in low- and middle-income countries; this is compounded by rapid urbanization.
The innovative approach is being tested on three continents: in Mongolia, Senegal, and Brazil.
Novartis reaches agreement with Pakistan to supply medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
May 12, 2017 /3BL Media/ -- We are pleased to announce that Novartis and the Ministry of National Health Services, Regulation and Coordination of the Islamic Republic of Pakistan have signed a Memorandum of Understanding to implement Novartis Access in Pakistan. Novartis Access medicines will be made available to the poorest population through hospitals under the Prime Minister’s National Health Insurance Program.
More than half the ASEAN region’s 630 million people are under age 30. Harald Nusser, Head of Novartis Social Business, says that to fight the rise of chronic disease in South East Asia we need to inform its youth on the importance of healthy lifestyles.